ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst - ARS Pharmaceuticals ( NASDAQ:SPRY )
Earlier this month, the FDA approved ARS Pharmaceuticals Inc's SPRY neffy ( epinephrine nasal spray ) for the emergency treatment of allergic reactions ( Type I ) , including those that are life-threatening ( anaphylaxis ) , for adult and pediatric patients.
| Ticker |
Sentiment |
Impact |
|
SPRY
|
Neutral
|
56 %
|
|
SNY
|
Neutral
|
24 %
|
